首页> 外文OA文献 >A Randomized Open Comparative Clinical Trial on the Effectiveness, Safety and Tolerability of a Homeopathic Medicinal Product for the Treatment of Painful Teething in Children
【2h】

A Randomized Open Comparative Clinical Trial on the Effectiveness, Safety and Tolerability of a Homeopathic Medicinal Product for the Treatment of Painful Teething in Children

机译:顺势疗法药物治疗儿童痛齿的有效性,安全性和耐受性的随机开放比较临床试验

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: Homeopathic products are sold over the counter and are often used for treatment of self-limiting complaints in children such as painful teething. Objective: To investigate the effectiveness, safety and tolerability of the homeopathic product ChamBell-5-02, in the treatment of children with painful teething in comparison to another homeopathic product. Design: A multicenter, randomized, open, comparative clinical trial with two parallel treatment groups at three outpatient pediatric clinics in Russia. Methods: Children aged ≤ six years with painful teething were enrolled from March-July 2009 in the study and randomized to receive either ChamBell-5-02 tablets (Dentokind®; intervention group) or homeopathic suppositories (Viburcol®; control group). Exclusion criteria were: fever of ≥38°C and severe comorbidity. Primary effectiveness endpoints were change of total severity scores of subjective complaints (TSSC) and clinical signs (TSCS) rated by investigators after seven days of treatment. Treatment satisfaction and safety (via number of adverse events (AEs)) were assessed. Results: A total of 200 children (100 per group) were included and analyzed. TSSC/ TSCS decreased after the 7- day treatment period from median 7.0 to 1.0/6.0 to 1.0 points in the intervention group and from median 5.0 to 1.0/5.5 to 1.0 points in the control group. Compared to the control group children receiving ChamBell-5-02 had about five/2.5 time higher odds of showing improvement (TSSC/TSCS: odds ratio resulting from proportional odds model was 5.1 (95%-CI: 2.7-9.4, p<0.0001) / 2.5 (95%-CI: 1.5-4.4, p=0.0011). Furthermore the intervention group showed a more favorable outcome regarding treatment satisfaction (ratings very satisfied: intervention group: n=94; control group: n=58). No AEs were recorded in the intervention group. In the control group three mild to moderate, nonserious AEs occurred. Conclusions: Overall it can be concluded that in this study ChamBell-5-02 tablets showed to be effective, safe and well tolerated.  
机译:背景:顺势疗法产品在柜台上出售,通常用于治疗儿童的自限性不适,例如出牙痛。目的:与其他顺势疗法产品相比,研究顺势疗法产品ChamBell-5-02在治疗牙齿痛的儿童中的有效性,安全性和耐受性。设计:俄罗斯三个门诊儿科诊所的两个平行治疗组的多中心,随机,开放,比较临床试验。方法:从2009年3月至7月,纳入年龄小于等于6岁且牙齿痛的儿童,并随机接受ChamBell-5-02片剂(Dentokind®;干预组)或顺势栓剂(Viburcol®;对照组)。排除标准为:≥38°C发烧和严重合并症。主要有效性终点是治疗7天后,研究者对主观主诉(TSSC)和临床体征(TSCS)的总严重程度评分的变化。评估治疗的满意度和安全性(通过不良事件(AE)的数量)。结果:总共包括200名儿童(每组100名)并进行了分析。治疗7天后,TSSC / TSCS从干预组的中位数7.0降低到1.0 / 6.0到1.0点,对照组从5.0的中位数降低到1.0 / 5.5到1.0点。与对照组相比,接受ChamBell-5-02的儿童表现出改善的几率高约5 / 2.5倍(TSSC / TSCS:由比例赔率模型得出的赔率比为5.1(95%-CI:2.7-9.4,p <0.0001) )/ 2.5(95%-CI:1.5-4.4,p = 0.0011)。此外,干预组在治疗满意度方面显示出更有利的结果(评分非常满意:干预组:n = 94;对照组:n = 58)。干预组未见不良事件,对照组出现三例轻度至中度,非严重不良事件结论:总的来说,可以得出结论,在该研究中,ChamBell-5-02片剂显示出有效,安全且耐受性良好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号